Navigation Links
Small molecule inhibitor of cholera discovered

Study appears in ScienceJust as hurricanes in the Gulf states and Guatemala have raised the risks of cholera outbreaks, researchers at Harvard Medical School have identified a new type of antibiotic against the cholera bacteria. While traditional antibiotics kill bacteria outright by interfering with processes essential for their survival, the new agent blocks production of bacterial proteins that cause the severe diarrhea associated with Vibrio cholerae infection.

"What we have done is made a custom, organism-specific antibiotic against Vibrio cholerae," said John Mekalanos, the Adele Lehman professor of microbiology and molecular genetics at HMS and the senior author on a report of the work appearing in today's online edition of Science.

Using a high-throughput screen of 50,000 small molecule candidate compounds, Mekalanos and lead author Deborah Hung identified several that turned off the expression of virulence proteins, factors that help the bacteria invade its human host and cause disease. They then showed that the most promising compound prevented cholera bacteria from setting up an infection when introduced into the digestive tract of mice.

Since most disease-causing organisms use elaborate virulence factors such as toxins to do their damage, the new approach should be widely applicable. "There is no reason our results cannot be replicated for a number of other important pathogens," Mekalanos said.


'"/>

Source:Harvard Medical School


Page: 1

Related biology news :

1. Small species back-up giant marsupial climate change extinction claim
2. Small worm yields big clue on muscle receptor action
3. Small molecule interactions were central to the origin of life
4. Small, smaller, smallest -- The plight of the vaquita
5. Small molecule dervived from Rb2/p130 could act as cancer therapeutic
6. Smallpox outbreak: How long would it take for vaccines to protect people? Would it work?
7. Chemists create Superbowl molecule; May lead to better health
8. Key molecule in plant photo-protection identified
9. Inflammatory molecules released by pollen trigger allergies
10. Researchers discover molecule that causes secondary stroke
11. Yale researchers identify molecule for detecting parasitic infection in humans
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... -- Summary This report provides all the information ... and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ...
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... On Thursday, March 23, 2017, ... down 0.07%; the Dow Jones Industrial Average edged 0.02% ... closed at 2,345.96, marginally dropping 0.11%. US markets saw ... 4 sectors finished in red, and 1 sector ended ... reports coverage on the following Biotechnology equities: BioDelivery Sciences ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... viscoelastic material that exhibits both viscous and elastic characteristics when deformed, which is ... polymer exhibits properties to gently absorb compressive forces and return to its natural ...
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
Breaking Biology Technology: